Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

CanSinoBIO finds no cases of blood clots from its Covid vaccine despite similarities with Johnson & Johnson
Published on: 2021-04-15
Share to
User Rating: / 0
PoorBest 

China’s CanSino Biologics on Wednesday sought to distance its Covid-19 vaccine from concerns that products made using a similar technology could be linked to rare events of serious blood clotting.
 

The company said no serious adverse events related to blood clots had been reported among the almost 1 million doses of its Covid-19 vaccine that had been administered to date. The product is licensed in China, Pakistan, Mexico and Hungary.
 

The statement came after the US Food and Drug Administration on Tuesday called for a pause in the roll-out of a vaccine made by American firm Johnson and Johnson, pending its review of six cases of severe blood clots among the 6.8 million people injected with it.
 

The US recommendation came on the heels of a finding last week from the EU’s European Medicines Agency (EMA) of a possible link between a vaccine made by British-Swedish firm AstraZeneca – of which more than 30 million doses have been administered in Europe – and rare cases of blood clots.
 

While the technology is the same for all four products, their developers used different formulations of adenoviruses to construct their vaccines.
 

CanSino’s product is based on a common cold virus known as Ad5, while Johnson and Johnson used a rarer human adenovirus. The Gamaleya Institute used a combination of the two for its Sputnik V vaccine, and AstraZeneca relied on a virus found in chimpanzees.
 

美国强生疫苗被暂停康希诺回应:技术不同、未有血栓报告

英国开发的阿斯利康新冠疫苗出现血栓问题之后被多国暂停,美国强生公司的疫苗日前也同样被暂停。
 

强生的新冠疫苗也跟血栓不良反应有关,有6名美国民众接种后出现了罕见的血栓症状,被医生诊断为“脑静脉窦血栓”,并伴有血小板下降。
 

随后美国食品药品监督管理局(FDA)和疾病预防控制中心(CDC)联合发布声明,建议暂停该疫苗的接种。
 

阿斯利康、强生的疫苗都是基于腺病毒技术的,国内也有一款疫苗是走这条技术路线的,那就是康希诺的Ad5-nCoV疫苗,因此这款疫苗是否与血栓有关也引发了关注。
 

今天康希诺公司在港交所发表公告,称本公司与阿斯利康新冠疫苗所使用的黑猩猩腺病毒载体和强生新冠疫苗所使用的26型腺病毒载体不同。
 

截至本公告日,接种重组新型冠状病毒疫苗Ad5-nCoV的约百万人中未收到与血栓相关的严重不良事件的报告。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2021 BusinessTianjin.com. All rights reserved.